Skip to main content
. Author manuscript; available in PMC: 2020 Jun 23.
Published in final edited form as: Thromb Res. 2015 Jul 17;136(3):582–589. doi: 10.1016/j.thromres.2015.07.011

Table 2. Relative risks (RR) of recurrent VTE and major bleeding – Network meta-analysis.

Relative risks (with 95% CIs in round brackets) above the diagonal pertain to recurrent VTE (transparent background), whereas estimates below the diagonal pertain to major bleeding (gray background). The reference category for the respective comparison is always higher to the left, e.g. the RR of 0.72 (bottom left box) represents the comparison of VKA with DOAC using VKA as the reference. Here, an RR of 0.72 is in favor of DOAC. (2A) Estimates from the unadjusted network meta-analysis. (2B) Estimates from a network meta-analysis adjusted to a 10% six-month risk of recurrent VTE in the VKA arm (efficacy), and a 5% six-month risk of major bleeding in the VKA arm (safety).

2A. Unadjusted Network Meta-Analysis
VKA 0.60 (0.45-0.79) 0.65 (0.38-1.09)
1.08 (0.70-1.66) LMWH 1.08 (0.59-1.95)
0.72 (0.39-1.37) 0.67 (0.31-1.46) DOAC
2B. Adjusted Network Meta-Analysis*
VKA 0.67 (0.46-0.97) 0.93 (0.20-4.40)
1.30 (0.83-2.05) LMWH 0.71 (0.14-3.51)
0.52 (0.21-1.29) 0.40 (0.15-1.19) DOAC